Complete Guide to Ayyar mPBPK Pharmacokinetics
Overview
Ayyar mPBPK is a GalNAc-siRNA used in the Rare disease therapeutic area. It is indicated for Acute hepatic porphyria. Interactive givosiran PBPK-PD simulator based on Ayyar and Song 2024 with rat, monkey, and human scenarios for plasma PK, tissue distribution, RISC loading, and ALAS1 response.
Mechanism of Action
Ayyar mPBPK exerts its pharmacological effect by targeting ALAS1. As a GalNAc-siRNA, it modulates this target to achieve therapeutic efficacy in Acute hepatic porphyria. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Mechanistic translational PBPK-PD models for Ayyar mPBPK:
| Parameter | Value |
|---|---|
| f sc | 0.9 |
| kd nM | 27.7 |
| notes | Human tissue and PD outputs are exploratory mechanistic projections; human plasma PK is the directly validated clinical output. |
| koff h | 1.32 |
| sc50 ng g | 6.1 |
| human ka h | 0.036 |
| human vc L | 2.8 |
| human kint h | 1.9 |
| risc total nM | 30 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Ayyar mPBPK is administered via the SC, IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Rare disease therapeutic area, for the treatment of Acute hepatic porphyria, understanding the pharmacokinetics of Ayyar mPBPK is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Ayyar mPBPK pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Ayyar mPBPK PK Simulator
Explore Ayyar mPBPK pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Ayyar mPBPK?
The elimination half-life of Ayyar mPBPK depends on patient-specific factors. Use our interactive Ayyar mPBPK PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Ayyar mPBPK administered?
Ayyar mPBPK is administered via the SC, IV route. It is indicated for Acute hepatic porphyria. As a GalNAc-siRNA, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Ayyar mPBPK?
Key pharmacokinetic parameters for Ayyar mPBPK include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Ayyar mPBPK dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Ayyar mPBPK PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.